Elevance Health, Inc. (ELV)

Over the past six months, Elevance Health's stock (ELV) has experienced several notable events and price movements. In July 2025, the company reported its second-quarter results and revised its full-year EPS guidance downwards, leading to a drop in the stock price. In October 2025, Elevance Health reported its Q3 earnings, beating estimates, but the results fell below expectations due to elevated medical costs within its Medicaid business. In December 2025, Elevance Health announced a quarterly dividend of $1.71. In January 2026, Wolfe Research upgraded Elevance Health's stock rating, and Wells Fargo raised its price target, leading to a jump in shares.

Demand seasonality for Elevance Health's products and services is influenced by annual enrollment periods, Medicare Part D seasonality, Medicaid and ACA trends, and membership fluctuations. The Inflation Reduction Act (IRA) has shifted Medicare Part D seasonality, impacting Elevance Health's earnings distribution. The company has noted elevated medical cost trends in its Medicaid and ACA health plans, which can impact profitability. Medical membership can fluctuate throughout the year. Elevance Health actively prepares for the upcoming year, including repricing products and anticipating regulatory changes.

Elevance Health, Inc. (ELV) is a prominent health company in the United States, operating in the Healthcare sector, specifically in the Managed Health Care and Healthcare Plans industry. The company provides a broad spectrum of health insurance products and related services to individuals, families, employers, and government programs across the U.S. Its portfolio is structured across four main segments: Health Benefits, CarelonRx, Carelon Services, and Commercial and Specialty Business. The company's services are delivered under various brands, including Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon.

Elevance Health's primary geographic footprint is within the United States, serving millions of members nationwide. A significant aspect of its geographic presence is its role as the exclusive licensee of the Blue Cross Blue Shield brand in 14 states. Through strategic acquisitions, Elevance Health has expanded its reach beyond these 14 states, particularly in government-sponsored programs like Medicaid and Medicare Advantage. For 2025, Elevance Health is expanding its individual and family Affordable Care Act (ACA) plans in Florida, Maryland, and Texas under the WellPoint brand.

Elevance Health's brand reputation in the past year appears to be generally stable, with a focus on its mission to improve lives and simplify healthcare. However, elevated medical cost trends and Q3 2025 earnings that missed expectations due to Medicaid costs could impact public perception. The company's commitment to governance excellence and expansion of its virtual assistant can positively reinforce its image. Significant investments in technology, analytics, and AI can enhance the company's reputation as an innovator.

Elevance Health, Inc. (ELV) has a diverse ownership structure, with a significant portion held by institutional investors. Approximately 77.92% to 89.92% of the company's stock is owned by institutional investors. Insiders own about 0.15% to 0.29% of the stock, while public companies and individual investors hold approximately 21.93% to 22.73%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. Recent institutional activity shows that DAVENPORT & Co LLC holds the top institutional stake. In the past 90 days, there have been no reported insider trading transactions.